NCT02584777View on ClinicalTrials.gov

A Phase II Non-Controlled, Open-Label, Efficacy, Safety, Pharmacokinetic, and Pharmacodynamic Study of Pacritinib in Myelofibrosis

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

November 30, 2015

Primary Completion Date

September 30, 2017

Study Completion Date

August 31, 2020

Conditions
Primary Myelofibrosis
Interventions
BIOLOGICAL

Pacritinib

QD (Once a day)

Sponsors

Collaborators (1)

CTI BioPharma
All Listed Sponsors
collaborator

CTI BioPharma

INDUSTRY

lead

Baxalta now part of Shire

INDUSTRY